Literature DB >> 12517775

Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation.

Oleg Tikhomirov1, Graham Carpenter.   

Abstract

The ansamycin antibiotic geldanamycin (GA) induces the intracellular degradation of ErbB-2/neu. Degradation of ErbB-2 proceeds through cleavage(s) within the kinase domain, resulting in the formation of a 135 kDa ectodomain fragment and a fragment(s) of approximately 50 kDa containing the COOH-terminal region. On the basis of independent means of identification, two adjacent sequence motifs have been identified in ErbB-2 that are required for GA-induced degradation. These motifs encompass residues 776-783 and 784-786 within the NH(2)-terminal lobe of the ErbB-2 kinase domain. This is also a region in which the epidermal growth factor receptor and ErbB-2 kinase domains differ significantly in sequence. Although mutations in this region abrogate GA-induced ErbB-2 degradation, the tyrosine kinase activity of ErbB-2 is not disrupted. Interestingly, these ErbB-2 mutants are specifically resistant to GA-induced degradation but retain sensitivity to other drugs, such as staurospore and curcumin, which are also able to provoke ErbB-2 degradation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12517775

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  Colorectal cancer: chemopreventive role of curcumin and resveratrol.

Authors:  Vaishali B Patel; Sabeena Misra; Bhaumik B Patel; Adhip P N Majumdar
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

2.  Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus.

Authors:  Mads Lerdrup; Silas Bruun; Michael V Grandal; Kirstine Roepstorff; Malene M Kristensen; Anette M Hommelgaard; Bo van Deurs
Journal:  Mol Biol Cell       Date:  2007-07-11       Impact factor: 4.138

3.  Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context.

Authors:  Maria A Theodoraki; Mary Kunjappu; David W Sternberg; Avrom J Caplan
Journal:  Exp Cell Res       Date:  2007-07-06       Impact factor: 3.905

Review 4.  The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts.

Authors:  William B Pratt; Yoshihiro Morishima; Yoichi Osawa
Journal:  J Biol Chem       Date:  2008-05-30       Impact factor: 5.157

5.  HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.

Authors:  Delphine R Boulbes; Stefan T Arold; Gaurav B Chauhan; Korina V Blachno; Nanfu Deng; Wei-Chao Chang; Quanri Jin; Tzu-Hsuan Huang; Jung-Mao Hsu; Samuel W Brady; Chandra Bartholomeusz; John E Ladbury; Steve Stone; Dihua Yu; Mien-Chie Hung; Francisco J Esteva
Journal:  Mol Oncol       Date:  2014-11-11       Impact factor: 6.603

6.  Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin.

Authors:  Peter Tsvetkov; Gad Asher; Veronica Reiss; Yosef Shaul; Leo Sachs; Joseph Lotem
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-04       Impact factor: 11.205

7.  Geldanamycin selectively targets the nascent form of ERBB3 for degradation.

Authors:  Candice S Gerbin; Ralf Landgraf
Journal:  Cell Stress Chaperones       Date:  2010-01-19       Impact factor: 3.667

8.  Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK.

Authors:  Sanjay Kansra; Stefan W Stoll; Jessica L Johnson; James T Elder
Journal:  Mol Biol Cell       Date:  2004-07-14       Impact factor: 4.138

9.  Regulation of the Src family kinase Lck by Hsp90 and ubiquitination.

Authors:  Ana Giannini; Marie-José Bijlmakers
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

10.  A multi-factor model for caspase degradome prediction.

Authors:  Lawrence J K Wee; Joo Chuan Tong; Tin Wee Tan; Shoba Ranganathan
Journal:  BMC Genomics       Date:  2009-12-03       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.